G. Wcisło

发表

Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature

C. Szczylik, G. Wcisło, K. Szarlej-Wcisło, 2007, Journal of Cancer Research and Clinical Oncology.

Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.

W. Kozlowski, C. Szczylik, C. Szczylik, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adiuvant therapy of colorectal cancer

C. Szczylik, L. Bodnar, G. Wcisło, 2006 .

Renal nephroprotection during chemotherapy with platinum compounds in cancer patients

C. Szczylik, L. Bodnar, G. Wcisło, 2003 .

[Cystatin C as a marker of glomerular filtration rate in patients with ovarian cancer].

C. Szczylik, L. Bodnar, G. Wcisło, 2008, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study.

C. Szczylik, L. Bodnar, G. Wcisło, 2008, European journal of cancer.

Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies

K. Brodaczewska, C. Kieda, C. Szczylik, 2020, International journal of molecular sciences.

[Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers].

C. Szczylik, L. Bodnar, G. Wcisło, 2014, Ginekologia polska.

Colorectal Cancer Prevention by Wheat Consumption: A Three-Valued Logic – True, False, or Otherwise?

G. Wcisło, K. Szarlej-Wcisło, 2014 .

[Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation].

C. Szczylik, L. Bodnar, G. Wcisło, 2012, Ginekologia polska.

Immunotherapy Resistance Mechanisms in Renal Cell Cancer

S. Chouaib, A. Czarnecka, C. Szczylik, 2014 .

Experience in Hepatic Arterial Infusion (HAI) with 5FU Due to Liver Metastases in Patients (Pts) with Colorectal Cancer (CC)

G. Wcisło, W. Pawlak, K. Brzozowski, 2003 .

Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance

C. Kieda, A. Czarnecka, C. Szczylik, 2018, Contemporary oncology.

Role of WNT/&bgr;‐Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines

C. Szczylik, R. Stec, L. Bodnar, 2018, Clinical genitourinary cancer.

Magnesium Salts in a Cancer Patient: Pathobiology and Protective Functions

L. Bodnar, G. Wcisło, 2013 .

The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review.

C. Szczylik, G. Wcisło, Jee-Yeong Jeong, 2010, Biochimica et biophysica acta.

Disturbances of Lipid Metabolism in a Cancer Cell and How This Knowledge Increases Its Role in Clinical Oncology

G. Wcisło, K. Szarlej-Wcisło, 2016 .

Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients

C. Szczylik, L. Bodnar, B. Górski, 2016, Hereditary cancer in clinical practice.

Status of the BRCA1 gene and incidence of hereditary ovarian cancer

C. Szczylik, L. Bodnar, G. Wcisło, 2010 .

Resveratrol Inhibitory Effects against a Malignant Tumor

G. Wcisło, 2014 .

Biological Activity of Resveratrol on an Ovarian Cancer Cell

L. Bodnar, G. Wcisło, K. Szarlej-Wcisło, 2014 .

[The role of the Fanconi anemia pathway in the pathophysiology of ovarian cancer].

C. Szczylik, G. Wcisło, A. Synowiec, 2015, Ginekologia polska.

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors

N. Rosenfeld, T. Eisen, A. Matakidou, 2020, Genome Medicine.

Comprehensive characterisation of cell-free tumour DNA in plasma and urine of patients with renal tumours

N. Rosenfeld, T. Eisen, A. Matakidou, 2019, bioRxiv.

Human Immunodeficiency Virus Infection–Associated Cancer and Mycotoxins in Food

G. Wcisło, K. Szarlej-Wcisło, 2015 .

Advanced renal cell carcinoma: pathology and systemic therapy with a new role of zoledronic acid in management of skeletal metastases

G. Wcisło, 2005 .

Locoregional chemotherapy in primary and secondary neoplasms of the liver - review of the literature

G. Wcisło, W. Pawlak, K. Brzozowski, 2003 .

Cancer Chemoprevention by Resveratrol Treatment

G. Wcisło, K. Szarlej-Wcisło, J. Korniluk, 2014 .

The role of tumor necrosis factor (TNF-alpha) in therapy of malignant diseases

G. Wcisło, K. Szarlej-Wcisło, R. Duchnowska, 2003 .

Cystatin C as a Parameter of Glomerular Filtration Rate in Patients with Ovarian Cancer

C. Szczylik, R. Stec, M. Smoter, 2010, Kidney and Blood Pressure Research.

Pathophysiological basis for utility of zoledronic acid in patients with prostate cancer

G. Wcisło, 2008 .

[CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].

C. Szczylik, L. Bodnar, G. Wcisło, 2008, Ginekologia polska.

Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy

K. Brodaczewska, C. Kieda, C. Szczylik, 2023, International journal of molecular sciences.

Salvage therapy with topotecan in heavily pretreated ovarian cancer patients

C. Szczylik, M. Smoter, L. Bodnar, 2009, Journal of Cancer Research and Clinical Oncology.

[An early diagnosis of colorectal cancer].

G. Wcisło, S. Wojtuń, J. Korniluk, 2004, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors

N. Rosenfeld, T. Eisen, A. Matakidou, 2020, Genome Medicine.